Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.23.16_SUPPL.3113PMID 28014840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Promising Experimental Therapies for Metastatic Melanoma

  2011cites this paper
• Immunotherapy of distant metastatic disease

  2009cites this paper
• Melanoma and immunotherapy.

  2009cites this paper
• Neue Therapiestrategien beim malignen Melanom

  2009cites this paper
• Melanoma and Immunother apy

  2009cites this paper
• Novel therapeutics for melanoma

  2009cites this paper
• Integrins in Angiogenesis

  2008cites this paper
• Integrins in prostate cancer progression.

  2008cites this paper
• Molecular Targeting in Hepatocellular Carcinoma

  2008cites this paper
• Integrins: Targets for Anti-Angiogenic Therapy

  2008cites this paper
• Monoclonal antibody 14C5 targets integrin αvβ5

  2008cites this paper
• Alpha-v Integrins as Therapeutic Targets in Oncology

  2007influential citation
• Novel therapeutic agents in ovarian cancer.

  2006cites this paper
• A Review of Antibody Therapeutics and Antibody-Related Technologies for Oncology

  2006cites this paper
• Molecularly targeted therapy for melanoma

  2006cites this paper
• Targeting integrin structure and function in disease.

  2006cites this paper
• c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model

  2006cites this paper
• A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens.

  2006cites this paper
• Angiogenesehemmung in der Onkologie

  2006cites this paper
• Integrins: Molecular targets in cancer therapy

  2006cites this paper
• Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding

  2005cites this paper